Format

Send to

Choose Destination
Invest New Drugs. 2017 Oct;35(5):669. doi: 10.1007/s10637-017-0479-3.

Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.

Author information

1
Sarah Cannon Research Institute, 93 Harley St, Marylebone, London, W1G 6AD, UK. jinfante@tnonc.com.
2
Tennessee Oncology, PLLC, 250 25th Ave North, Nashville, TN, 37203, USA. jinfante@tnonc.com.
3
Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.
4
California PacificMedical Center (Sutterhealth), 475 Brannan Street, Suite 220, San Francisco, CA, 94107, USA.
5
Sarah Cannon Research Institute, 93 Harley St, Marylebone, London, W1G 6AD, UK.
6
Tennessee Oncology, PLLC, 250 25th Ave North, Nashville, TN, 37203, USA.
7
AstraZeneca, 1800 Concord Pike, Wilmington, DE, 19850, USA.
8
AstraZeneca, Charter Way, Macclesfield, SK10 2NA, UK.
9
Yale Cancer Center, 55 Park Street, Ste First Floor, New Haven, CT, 06519, USA.
PMID:
28676972
DOI:
10.1007/s10637-017-0479-3

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center